- EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A
- Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology
- Bulletin from Swedish Orphan Biovitrum (Sobi)'s Annual General Meeting (AGM)
- Sobi publishes Q1 2023 report: Continued solid progress
- Sobi to streamline nirsevimab contractual arrangements
- Sobi® publishes Annual and sustainability report for 2022
- Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)
- Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB
More ▼
Key statistics
On Friday, Swedish Orphan Biovitrum AB (publ) (SOBI:STO) closed at 213.00, 6.98% above its 52-week low of 199.10, set on Oct 28, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 211.60 |
---|---|
High | 215.60 |
Low | 211.60 |
Bid | -- |
Offer | -- |
Previous close | 212.00 |
Average volume | 401.36k |
---|---|
Shares outstanding | 309.80m |
Free float | 306.25m |
P/E (TTM) | 20.14 |
Market cap | 65.99bn SEK |
EPS (TTM) | 10.58 SEK |
Data delayed at least 15 minutes, as of Jun 02 2023 17:00 BST.
More ▼